Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer’s disease: a qualitative interview study
Artículo
Acceso abierto
Artículo
DOAJ
Abstract Background Recruitment and retention remain persistent challenges in Alzheimer’s disease (AD) clinical trials, particularly as studies increasingly focus on earlier disease stages and require longer participat...
LCC TENDOk1lZGljaW5lIChHZW5lcmFsKQ~~Idioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access